Separate names with a comma.
My pleasure. At HEI we try to be different than everyone else. I've tried to make it more personal by responding to emails, texts, forums, etc. I...
A huge thank you to everyone on here. I hope you all will still consider supporting HEI's research efforts. Right now, any new donor has their...
This is a report from our COO of HEI and our research team on the milestones this year with our proof-of-concept study: We were able to develop a...
Keep in mind this was an article written by a reporter. They don't always get the facts straight. Before we got connected to Dr. Kesari were...
To speed things up takes money. We are a non-profit that relies on government funding and private donations. The two-year proof-of-concept study...
Hi! I was in the room training the lady you spoke to. Let me clear up a few things that got misunderstood. NHPN-1010 is in a proof-of-concept...
The real term is expanded use. Read more here: https://www.fda.gov/news-events/public-health-focus/expanded-access Read more here:...
Yes, the cause of one condition can be the cause of a second condition. So, the mechanism of how the drug works can have multiple uses. Also, the...
Or blast-induced. There are probably several "causes" of tinnitus. We are going after the most prevalent one, at least what is thought to be the...
Incorrect, the article says patient, singular. Not plural. We also are unsure how accurate this article is and are inquiring. Sometimes we are the...
We have data on the pill's efficacy in pre-clinical trials for SNHL, ototoxicity, and tinnitus. We believe it might also be helpful with...
We don't know yet. The questions you are asking are generally found when dosing is determined, which is Phase II and III clinical trials. Our...
Expanded Use is typically done on a case-by-case basis. Reading the article, it talks about "a chronic tinnitus patient." NOT patients, plural....
Hi everyone, @Markku asked me to jump on real quick and give everyone an update on the news article from koreamed.com. I read through some of...
We didn't choose cochlear implant trauma. Which indication they (the biotech firm) choose is still in the air right now. The delays in clinical...